ArticleScientific reports2025

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib.

Huaxiang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.